11/11/2016
HYMOVIS® RECEIVES PERMANENT, PRODUCT-SPECIFIC J-CODE FROM THE CENTER FOR MEDICARE AND MEDICAID SERVICES (CMS)
HYMOVIS® offers a convenient two-dose regimen
Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services (“CMS”) has assigned its product HYMOVIS® a unique Healthcare Common Procedure Coding System (“HCPCS”) code, or J-Code.
The new J-Code provides reimbursement coding to healthcare professionals that administer HYMOVIS® and becomes effective on January 1, 2017.
The new J-Code provides reimbursement coding to healthcare professionals that administer HYMOVIS® and becomes effective on January 1, 2017.